Tags : Combination Regimen

Noxopharm Collaborates with GenesisCare to Bring Combination Regimen of Veyonda

Shots: The collaboration offers a compassionate access program to make the combination therapy of Veyonda & 7Lu-PSMA available to the patients suffering from mCRPC, being treated with theranostics in Australia The combination regimen is currently being evaluated in clinical studies in patients with advanced mCRPC, demonstrating improvement in response rate with mOS (17.1mos.) and a […]Read More

Janssen Reports Submission of sBLA to the US FDA for

Shots: The sBLA is based on P-III CANDOR study assessing Darzalex + carfilzomib + dexamethasone (DKd) vs Kd as monothx. in 466 patients with r/r MM prior treated with 1L+ therapies at 120 sites globally The results of P-III CANDOR study support the benefits of triple regimen for patients with MM with 1EPs as PFS […]Read More

Janssen’s Darzalex (daratumumab) Combination Regimen Receives EC’s Approval for Transplant

Shots: The approval is based on P-III CASSIOPEIA studyassessingDarzalex + bortezomib, thalidomide and dexamethasone (VTd) vs VTd in 1085 newly diagnosed patients with previously untreated, symptomatic MM, who were eligible for high-dose CT and stem cell transplant The P-III CASSIOPEIA study results: higher sCR (29% vs 20%); @18.8mos. improvement in PFS (93% vs 85%), published […]Read More

Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for

Shots: The CHMP positive opinion is based on P-III CASSIOPEIA (MMY3006) study assessing the combination of Darzalex + bortezomib, thalidomide and dexamethasone vs bortezomib, thalidomide and dexamethasone alone in 1,085 newly diagnosed patients with previously untreated symptomatic MM, eligible for ASCT If approved, the combination regimen will be the first Darzalex based regimen that would […]Read More